Mitochondrial inhibitor atovaquone increases tumor oxygenation and inhibits hypoxic gene expression in patients with non-small cell lung cancer

Mitochondrial inhibitor atovaquone increases tumor oxygenation and inhibits hypoxic gene expression in patients with non-small cell lung cancer

<strong>Purpose:</strong> Tumor hypoxia fuels an aggressive tumor phenotype and confers resistance to anticancer treatments. We conducted a clinical trial to determine whether the antimalarial drug atovaquone, a known mitochondrial inhibitor, reduces hypoxia in non-small cell lung cancer...

Full description

Bibliographic Details
Main Authors: Skwarski, M, McGowan, D, Belcher, E, Di Chiara, F, Stavroulias, D, McCole, M, Derham, J, Chu, K-Y, Teoh, E, Chauhan, J, O'reilly, D, Harris, B, Macklin, P, Bull, J, Green, M, Rodriguez Berriguete, G, Prevo, R, Folkes, L, Campo, L, Ferencz, P, Croal, P, Flight, H, Qi, C, Holmes, J, O'Connor, J, Gleeson, F, McKenna, WG, Harris, A, Bulte, D, Buffa, F, MacPherson, R, Higgins, G
Format: Journal article
Language:English
Published: American Association for Cancer Research 2021

Similar Items